Table 1 Clinical uses of NCTD in treatment of cancer patients and the related results and outcomes
Cancers | n | Therapies and usages of NCTD | Efficient (CR + PR) | Symptoms or LQ improving | Tumor marker decreasing | Tumor size reducing | Survival time prolonging | Side effects alleviating | References | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Method | Dose | Course | Group | |||||||||
PHC (I–III stage) | 244 | po or iv | 10 mg, tid; or 5–20 mg, qd, iv | 1–18 month |  |  | 58.6% | (AFP) 39% | Yes, 40.7% | MST 7 month 1 year SR 30% | Yes, WBC↑72% | [25] |
PHC (I–III stage) | 86 | iti | iti, 20 mg, qw po, 10 mg, tid | 4 weeks 3–6 months | iti vs. po |  | Yes, P < 0.05 | Yes, P < 0.05 | Yes, P < 0.05 | 1 year SR, P < 0.05 | Yes, P < 0.05 | [26] |
PHC (I–III stage) | 41 | iv + po | 10 mg, qd, iv 5 mg, qd, po | 1 month 1–3 months |  |  | Yes, P < 0.05 |  | Yes, 31.7% | MST 6.8 month 1 year SR 17.7% | Yes, WBC↑59% | [27] |
PHC (II–III stage) | 76 | po + Chem | po, 10 mg, tid Chem., FAM regimen | 3–12weeks | po + Chem vs. Chem |  | – | (AFP) 39% | 66% vs. 35% P < 0.05 | NS | NS | [28] |
PHC (II–III stage) | 75 | po + TCM | 10 mg, tid, po GFL, 10 tab, tid, po | 3 months | NCTD + GFL vs. NCTD or GFL |  | Yes | CR + PR, P < 0.05 84% vs. 7% or 53% | Yes | 1 year SR, P < 0.05 41% vs. 27% or 12% | Yes | [29] |
PHC (Ad) | 54 | iti | NCTD-P407, 2–4 ml, qw | 2–3 weeks | NCTD-P407 vs. TACE |  | Yes, P < 0.05 | NS | NS | NS | Yes, P < 0.05 | [30] |
PHC (Ad) | 56 | iti | NCTD-P407, 2–4 ml, qw Ethanol 4-8 ml, qw | 2–3 weeks 6–8 weeks |  |  | NS |  | NS | 1 year SR, P < 0.05 | NS | [31] |
PHC (Ad) | 80 | po + IVT | IVT, 1/m × 4 po, 5–10 mg, tid | 4 months 3 months | po + IVT vs. placebo + IVT placebo + IVT |  |  | Yes, P < 0.05 | Yes, P < 0.05 |  | Yes, P < 0.05 | [32] |
PHC (Ad) | 43 | iv + Chem | 30 mg, iv, qd × 10 5-FU + CF regimen | 20 days | iv + Chem vs. Chem |  | Yes, P < 0.05 |  | Yes, P < 0.05 |  | Yes, P < 0.05 | [33] |
PHC (Ad) | 47 | iv + TACE | 10–20 mg, iv qd | 1–2 months | iv + TACE vs. TACE |  | Yes, P < 0.05 |  | Yes, P < 0.05 |  |  | [34] |
PHC (Ad) | 60 | po + TCM | 10–15 mg, po, tid | 3 months | po + TCM vs. TCM | Yes, P < 0.05 | Yes, P < 0.05 |  |  |  |  | [35] |
PHC (Ad) | 79 | po + TCM | 15 mg, po, tid | 2 month | po + TCM vs. Chem/IVT |  | Yes, P < 0.05 |  | Yes, P < 0.05 | MST, 16 month vs. 11 month P < 0.01 | Yes, P < 0.05 | [36] |
SHC | 60 | po + Chem | 15 mg, po, tid | 3 months | po + Chem vs. Chem |  | Yes, P < 0.05 |  | Yes, P < 0.05 |  | Yes, P < 0.05 | [37] |
GC (Ad) | 50 | iv + Chem | 30 mg, iv qd × 7–10 | 6 weeks | iv + Chem vs. Chem | NS | Yes, P = 0.02 |  | NS |  | Yes, P < 0.05 | [38] |
GC II-III (post-op.) | 82 | po + Chem | 15 mg, po, tid PLF regimen | 6 months 4 weeks × 6 | po + Chem vs. Chem |  |  |  |  | 3 year SR, P < 0.05 3 year RR, P < 0.05 | Yes, P < 0.05 | [39] |
EC | 58 | iv + RT | 30 mg, iv, qd × 10 RT,200GY, qd × 5 | 4 weeks 2 weeks | iv + RT vs. RT | Yes, P < 0.05 | Yes, P < 0.05 |  | Yes, P < 0.05 |  | Yes, P < 0.05 | [40] |
CC (III stage) | 264 | iv + RT | 20–30 mg, iv, qd RT,20GY, qd × 5 | 6–8 weeks | iv + RT vs. RT |  |  |  | NS | Yes, P < 0.05 | Yes, P < 0.05 | [41] |
NHL | 86 | iv + Chem | 15–25 mg, iv, qd CHOP regimen | 2 weeks | iv + Chem vs. Chem | NS | Yes, P < 0.05 |  | NS | NS | Yes, P < 0.05 | [42] |
NHL | 57 | iv + Chem | 30–40 mg, iv, qd CTOP regimen | 2 weeks | iv + Chem vs. Chem | NS | Yes, P < 0.05 |  | NS |  | Yes, P < 0.05 | [43] |
LC (Ad) | 60 | iv + Chem | 20 mg, iv, qd × 7 CVI regimen | 9 weeks | iv + Chem vs. Chem |  |  |  | Yes, P < 0.05 |  | NS | [44] |
NSCLC (Ad) | 50 | iv + Chem | 20 mg, iv, qd × 7 DP regimen |  | iv + Chem vs. Chem |  |  |  | Yes, P < 0.05 |  | Yes, P < 0.05 | [45] |
NSCLC (III-IVstage) | 85 | iv + Chem | 60–100 ml, iv, qd × 14 PTC protocol | 8 weeks | iv + Chem vs. Chem | Yes, P < 0.05 | Yes, P < 0.05 |  | Yes, P < 0.05 |  | Yes, P < 0.01 | [46] |
NSCLC (III-IVstage) | 180 | iv + Chem | 30 mg, iv, qd × 21 GC protocol | 9 weeks | iv + Chem vs. Chem | Yes, P = 0.007 |  |  | Yes, P < 0.05 |  | Yes, P < 0.05 | [47] |
NSCLC (Ad) | 80 | iv + Chem | 40 ml, iv, qd × 14 DDP protocol | 8 weeks | iv + Chem vs. Chem | Yes, P < 0.05 | Yes, P < 0.01 |  | Yes, P < 0.05 |  | Yes, P < 0.01 | [48] |